Analysts Set Aquestive Therapeutics, Inc. (NASDAQ:AQST) Target Price at $7.83

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have been given a consensus recommendation of “Buy” by the seven research firms that are presently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $7.83.

A number of equities analysts recently issued reports on AQST shares. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a research report on Wednesday, August 14th. JMP Securities reiterated a “market outperform” rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a research report on Monday, August 12th.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Victory Capital Management Inc. acquired a new stake in Aquestive Therapeutics in the 2nd quarter valued at about $27,000. PFG Investments LLC lifted its holdings in Aquestive Therapeutics by 22.9% in the 2nd quarter. PFG Investments LLC now owns 59,000 shares of the company’s stock valued at $153,000 after acquiring an additional 11,000 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Aquestive Therapeutics in the 1st quarter valued at about $54,000. Financial Advocates Investment Management lifted its holdings in Aquestive Therapeutics by 70.0% in the 2nd quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock valued at $88,000 after acquiring an additional 14,000 shares during the last quarter. Finally, Lazard Asset Management LLC lifted its holdings in Aquestive Therapeutics by 115.5% in the 1st quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock valued at $124,000 after acquiring an additional 15,601 shares during the last quarter. 32.45% of the stock is owned by institutional investors and hedge funds.

Aquestive Therapeutics Stock Performance

Aquestive Therapeutics stock opened at $4.84 on Thursday. The company has a 50-day simple moving average of $3.79 and a 200-day simple moving average of $3.67. The firm has a market capitalization of $440.73 million, a P/E ratio of -11.52 and a beta of 2.84. Aquestive Therapeutics has a one year low of $1.25 and a one year high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.08. The firm had revenue of $20.10 million for the quarter, compared to the consensus estimate of $12.62 million. During the same quarter in the prior year, the company posted ($0.10) EPS. As a group, sell-side analysts forecast that Aquestive Therapeutics will post -0.47 earnings per share for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.